INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
Public company

PCVXVaxcyte, Inc.

CIK 0001649094

EDGAR filingsOpen in network
Disclosed transactions44
Buys / sells3 / 16
Max Insider Score46
Connections9with evidence

PCVX · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
6
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$21K
343 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Jodar LuisChief Medical Officer · Sep 9, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-09-04 · Sep 4, 2026
  • ← Lobbied forevidence
    BGR GOVERNMENT AFFAIRSLDA Q2 2026 second quarter · Health issues · Aug 26, 2026
9
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL
$116K
1,907 sh
Nov 2, 2026
Nov 4, 2026
traded Nov 2, 2026
+2d
SEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
3,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

10
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$147K
2,414 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

3
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$36K
586 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$78K
3,000 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
2,250 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$12K
2,250 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
19.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

19
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$1.56M
18.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

7
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
18.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

10
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$492K
19.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

20
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$1.65M
19.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

2
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$96K
18.0K sh
Oct 5, 2026Oct 7, 2026
traded Oct 5, 2026
+2dSEC FORM 4

Evidence

15
DS
Dhaliwal Harpreet S.Chief Technical Ops Officer
PCVXVaxcyte, Inc.
Tax withholding
F$462K
7,651 sh
Sep 8, 2026Sep 9, 2026
traded Sep 8, 2026
+1dSEC FORM 4

Evidence

11
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Tax withholding
F$330K
5,459 sh
Sep 8, 2026Sep 9, 2026
traded Sep 8, 2026
+1dSEC FORM 4

Evidence

20
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Open-market sale
SELL$79K
1,334 sh
Sep 9, 2026Sep 9, 2026
traded Sep 9, 2026
+0dSEC FORM 4

Evidence

26
WJ
Wassil JimEVP, Chief Scientific Ofc, COO
PCVXVaxcyte, Inc.
Open-market sale
SELL$84K
1,381 sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

15
JL
Jodar LuisChief Medical Officer
PCVXVaxcyte, Inc.
Grant or award
A—
52.6K sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

15
JL
Jodar LuisChief Medical Officer
PCVXVaxcyte, Inc.
Grant or award
A—
88.3K sh
Sep 4, 2026Sep 9, 2026
traded Sep 4, 2026
+5dSEC FORM 4

Evidence

9
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding
F$80K
1,327 sh
Sep 8, 2026Sep 9, 2026
traded Sep 8, 2026
+1dSEC FORM 4

Evidence

35
Gilbert Ray Cisneros, Jr.DSelf
PCVXVaxcyte, Inc.
Purchase
BUY$1,001 – $15KJul 16, 2026Sep 4, 2026
traded Jul 16, 2026
+50dHOUSE PTR

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding
F$20K
326 sh
Sep 2, 2026Sep 2, 2026
traded Sep 2, 2026
+0dSEC FORM 4

Evidence

5
DS
Dhaliwal Harpreet S.Chief Technical Ops Officer
PCVXVaxcyte, Inc.
Tax withholding
F$22K
361 sh
Aug 31, 2026Sep 2, 2026
traded Aug 31, 2026
+2dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding
F$15K
243 sh
Aug 31, 2026Sep 2, 2026
traded Aug 31, 2026
+2dSEC FORM 4

Evidence

5
DS
Dhaliwal Harpreet S.Chief Technical Ops Officer
PCVXVaxcyte, Inc.
Tax withholding
F$41K
659 sh
Sep 2, 2026Sep 2, 2026
traded Sep 2, 2026
+0dSEC FORM 4

Evidence

9
LJ
Lee JacksDirector
PCVXVaxcyte, Inc.
Grant or award
A—
11.4K sh
Jun 15, 2026Jun 16, 2026
traded Jun 15, 2026
+1dSEC FORM 4

Evidence

17
LJ
Lee JacksDirector
PCVXVaxcyte, Inc.
Grant or award
A—
2,265 sh
Jun 15, 2026Jun 16, 2026
traded Jun 15, 2026
+1dSEC FORM 4

Evidence

24
Gilbert Ray Cisneros, Jr.DSelf
PCVXVaxcyte, Inc.
Purchase
BUY$1,001 – $15KMay 12, 2026Jun 8, 2026
traded May 12, 2026
+27dHOUSE PTR

Evidence

20
Gilbert Ray Cisneros, Jr.DSelf
PCVXVaxcyte, Inc.
Purchase
BUY$1,001 – $15KMay 13, 2026Jun 8, 2026
traded May 13, 2026
+26dHOUSE PTR

Evidence

8
WJ
Wassil JimCHIEF OPERATING OFFICER
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$128K
2,250 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$78K
3,000 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

8
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$180K
3,000 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
3,000 sh
Apr 7, 2026Apr 8, 2026
traded Apr 7, 2026
+1dSEC FORM 4

Evidence

1
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
405 sh
Mar 17, 2026Mar 18, 2026
traded Mar 17, 2026
+1dSEC FORM 4

Evidence

4
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$82K
1,487 sh
Mar 17, 2026Mar 18, 2026
traded Mar 17, 2026
+1dSEC FORM 4

Evidence

2
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M$65K
2,500 sh
Mar 11, 2026Mar 11, 2026
traded Mar 11, 2026
+0dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Tax withholding · 10b5-1 plan
F$29K
495 sh
Mar 9, 2026Mar 11, 2026
traded Mar 9, 2026
+2dSEC FORM 4

Evidence

8
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Open-market sale · 10b5-1 plan
SELL$146K
2,500 sh
Mar 11, 2026Mar 11, 2026
traded Mar 11, 2026
+0dSEC FORM 4

Evidence

0
CE
Cowan ElviaSVP, Finance & CAO
PCVXVaxcyte, Inc.
Option exercise · 10b5-1 plan
M—
2,500 sh
Mar 11, 2026Mar 11, 2026
traded Mar 11, 2026
+0dSEC FORM 4

Evidence

40
DS
Dhaliwal Harpreet S.Chief Technical Ops Officer
PCVXVaxcyte, Inc.
Open-market sale
SELL$455K
9,743 sh
Dec 31, 2025Jan 2, 2026
traded Dec 31, 2025
+2dSEC FORM 4

Evidence

22
CE
Cowan ElviaSVP, FINANCE
PCVXVaxcyte, Inc.
Gift
G—
1,000 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

46
CE
Cowan ElviaSVP, FINANCE
PCVXVaxcyte, Inc.
Open-market sale
SELL$322K
6,716 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

39
CE
Cowan ElviaSVP, FINANCE
PCVXVaxcyte, Inc.
Open-market sale
SELL$235K
4,907 sh
Dec 23, 2025Dec 29, 2025
traded Dec 23, 2025
+6dSEC FORM 4

Evidence

  • ← Lobbied forevidence
    DCI GROUP, L.L.C.LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Lee JacksDirector · Jun 16, 2026
  • ← Insider ofevidence
    Wassil JimCHIEF OPERATING OFFICER · May 1, 2026
  • ← Insider ofevidence
    Dhaliwal Harpreet S.Chief Technical Ops Officer · Jan 2, 2026
  • ← Insider ofevidence
    Cowan ElviaSVP, FINANCE · Dec 29, 2025

    • Lobbying

    $310K reported · de-duplicated
    2026 Q2 $155K via firms2026 Q1 $155K via firms
    • BGR GOVERNMENT AFFAIRS$80K2026 Q1 · posted Aug 26, 2026 · Health issues
    • DCI GROUP, L.L.C.$75K2026 Q2 · posted Aug 26, 2026 · Health issues
    • BGR GOVERNMENT AFFAIRS$80K2026 Q2 · posted Aug 26, 2026 · Health issues
    • DCI GROUP, L.L.C.$75K2026 Q1 · posted Aug 26, 2026 · Health issues

    Connected PAC contributions

    FEC · direct to members

    No contributions from a PAC connected to this company.